Quetiapine (Elderly — Dementia Caution)
Brand names: Seroquel, Atrolak
Quetiapine is a second-generation (atypical) antipsychotic used in schizophrenia and bipolar disorder, and used with particular caution in older people.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
US labelling (FDA)
Reference — US labelling, may differ from UK2 DOSAGE & ADMINISTRATION · Quetiapine tablets, USP can be taken with or without food ( 2.1 ) Indication Initial Dose Recommended Dose Maximum Dose Schizophrenia-Adults (2.2) 25 mg twice daily 150 to 750 mg/day 750 mg/day Schizophrenia-Adolescents (13 to 17 years) (2.2) 25 mg twice daily 400 to 800 mg/day 800 mg/day Bipolar Mania- Adults Monotherapy or as an adjunct to lithium or divalproex (2.2) 50 mg twice daily 400 to 800 mg/day 800 mg/day Bipolar Mania- Children and Adolescents (10 to 17 years), Monotherapy (2.2) 25 mg twice daily 400 to 600 mg/day 600 mg/day Bipolar Depression-Adults (2.2) 50 mg once daily at bedtime 300 mg/day 300 mg/day Geriatric Use: Consider a lower starting dose …
Source: US FDA prescribing information (openFDA / DailyMed), label dated 2025-06-27. Accessed 2026-06-12. US dosing and indications can differ from UK practice — use UK sources for prescribing decisions.
Clinical monograph
How it works
It antagonises multiple receptors, including dopamine D2 and serotonin 5-HT2; antihistamine activity contributes to sedation.
Prescribing in practice
- In older people with dementia, antipsychotics increase the risk of stroke and death — use only when necessary, at the lowest dose for the shortest time.
- Metabolic effects (weight gain, raised glucose and lipids), sedation and postural hypotension occur; it can prolong the QT interval.
- Do not stop abruptly.
Monitoring
Monitor weight, glucose and lipids, blood pressure and (where relevant) ECG; review the need to continue, especially in dementia.
Counselling the patient
- Sedation and weight gain can occur.
- Rise slowly to avoid dizziness.
- Do not stop it suddenly.
Evidence & guidelines
Used in schizophrenia and bipolar disorder; antipsychotics in dementia carry a stroke and mortality warning and are restricted (MHRA; NICE NG97).
Reference: MHRA guidance 2004; NICE NG97; CATIE trial; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SCORE2-OP — 5/10-Year CVD Risk (Age ≥ 70) · Cardiovascular Risk
- Hearing Handicap Inventory for the Elderly — Screening (HHIE-S) · Hearing
- Clinical Frailty Scale (CFS) · Prognosis
- Confusion Assessment Method (CAM) · Cognitive Assessment
- Mini-Mental State Examination (MMSE) · Cognitive Assessment
- MoCA — Montreal Cognitive Assessment · Cognitive Assessment
- Falls Assessment in Older Adults · NICE CG161 2013
- Delirium Outside ICU · NICE CG103
- Comprehensive Geriatric Assessment (CGA) · BGS / NICE
- Delirium Assessment and Management · NICE CG103 2010
- Frailty Recognition and Management · BGS Frailty Framework / NHS NHSE
- Polypharmacy and Medicines Optimisation · STOPP/START v2 2014 / NICE NG5